The Anti‐Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer
Head & Neck · 2025
DOI: 10.1002/hed.70109 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Head & Neck, 2025. Verfasst von Hongxi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Neoplasm Recurrence, Local, Autoantibodies, Thyroid Cancer, Papillary. Die Arbeit nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Background
To explore the relationship between anti‐thyroglobulin antibody (TgAb) trajectories and recurrence risk in papillary thyroid cancer (PTC) patients.
Methods
This multiple‐center, retrospective cohort included 4161 patients who had no evidence of structural disease and a stimulated thyroglobulin (s‐Tg) of ≤ 10 ng/mL at the initial radioiodine (RAI) treatment. Among 3660 patients who had repeated TgAb measurements (before RAI treatment, 1, 6, or 12 months after treatment) and available response assessments, latent class models were used to identify TgAb trajectories. Associations of trajectories with the risk of recurrence were estimated.
Results
Four distinct TgAb trajectories were identified. Compared with patients belonging to the consistently negative trajectory, patients with the other three trajectories had higher risks of recurrence (medium‐level descent: odds ratio = 3.46 [95% CI = 1.56–6.90], high‐level descent: 8.04 [1.26–28.78], persistently increasing: 12.11 [5.73–23.75]).
Conclusions
TgAb trajectories within 1 year after RAI treatment are associated with the risk of recurrence in PTC patients with a s‐Tg ≤ 10 ng/mL. Trial Registration Registered at www.chictr.org.cn (identifier: ChiCTR2300075574)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Rong Tian
Förderung
- National Natural Science Foundation of China
- Science and Technology Department of Sichuan Province
Zitieren
APA
Wang, H., Tian, T., Li, Q., & Tian, R. (2025). The Anti‐Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer. Head & Neck. https://doi.org/10.1002/hed.70109
Vancouver
Wang H, Tian T, Li Q, Tian R. The Anti‐Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer. Head & Neck. 2025. doi:10.1002/hed.70109
BibTeX
@article{Wang2025,
author = {Wang, Hongxi and Tian, Tian and Li, Qianrui and Tian, Rong},
title = {The Anti‐Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.70109}
}
EUVIMED